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Abstract. The study of pharmacogenetics has
expanded from what were initially casual family-based
clinical drug response observations, to a fully-fledged
science with direct therapeutic applications, all within
a time-span of less than 60 years. A wide spectrum
of polymorphisms, located within several genes, are
now recognised to influence the pharmacokinetics and
pharmacodynamics of the majority of drugs within our
therapeutic armamentarium. This information forms
the basis for the new development of pharmacogenetic
genotyping tests, which can be used to predict the
therapeutic and/or adverse effects of a specific drug in
a particular patient. Pharmacogenetic-guided, patient
targeted therapy has now become the developing ful-
crum of personalized medicine, as it provides the best
means to optimize benefit/risk ratio in pharmacological
management.
Keywords Pharmacogenetics - targeted therapy - pre-
dictive biomarkers - personalized medicine.
1 Introduction
The understanding of molecular pathology of disease, to-
gether with the discovery of novel therapeutic targets,
has greatly enhanced the evolution of new drugs. On
the forefront of such discoveries lie the various biotech
drugs produced by recombinant DNA technology, such
as the anti-cancer drugs trastuzumab and ibrutinib; the
latter being granted a license by the FDA in February
2014 (FDA, 2014); as well as recent receptor-specific
ligands such as the angiotensin II receptor blocker azil-
sartan, which was approved by the FDA for use in hy-
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pertension management in February 2011 (FDA, 2011).
Although scientific knowledge in this area has been in-
creasing exponentially, it has frequently been observed
that different patients often exhibit altered responses to
such therapies. These responses may manifest as very
high or very low drug efficacy, or as an unexpected ad-
verse reaction in selected individuals. Genetic variation
is a common contributor to altered responses. Pharma-
cogenetics, a term first coined by Friedrich Vogel in 1959
(Vogel, 1959), is the study of the association between ge-
netic variation (most commonly single-nucleotide poly-
morphisms (SNPs) or microdeletions), and the efficacy
and toxicity of a drug.
2 Pharmacogenetic biomarkers
Pharmacogenetics more commonly deals with the identi-
fication of germ-line genetic variants as predictive mark-
ers of drug response. However, in some patient groups,
such as those suffering from cancer, genomic analysis
is possible both on germ-line DNA, often derived from
blood, as well as on somatic DNA, derived from tu-
mour tissue (biopsies or resections). Whereas germ-line
DNA variants are inherited in normal Mendelian fash-
ion, somatic DNA mutations represent the variations
associated with tumour initialisation and progression,
or secondary mutations due to the tumour itself (Ger-
linger et al., 2012). For example, genetic variations in
the genes that code for drug metabolising enzymes, such
as thiopurine-S-methyltransferase (TPMT), cytochrome
P450 2D6 (CYP2D6) and uridine-diphosphate glu-
curonosyltransferase 1A1 (UGT1A1) are germ-line poly-
morphisms useful for determining pharmacokinetically-
influenced pharmacological outcomes. Table 1 sum-
marises a few examples of such pharmacogenetic vari-
ability. On the other hand, acquired somatic muta-
tions in tumour tissue may regularly directly modify
the pharmacodynamics of drug response. Somatic mu-
Pharmacogenetics: the science of predictive clinical pharmacology 16
tations are exemplified by the presence of the BRC-ABL
(a reciprocal chromosomal translocation between chro-
mosomes 9 and 22, resulting in the generation of a fu-
sion gene, consisting of the chromosome 9 ABL1 gene
and part of the BCR gene on chromosome 22) translo-
cation in chronic myeloid leukaemia (CML), the overex-
pression of human Epidermal Growth Factor Receptor
2 (HER2) in breast cancer, BRAF (a gene coding for
serine/threonine-protein kinase B-Raf involved in cell-
growth signalling) mutations in metastatic melanoma,
and Epidermal Growth Factor Receptor (EGFR) mu-
tants in lung cancer. The abnormal functioning of these
oncogenic proteins promotes cell transformation. The
transformed cells become dependent on the oncogenic
stimulus and hence provide a therapeutic opportunity,
due to the increased sensitivity of the transformed cells
to specific inhibitors. This is the basis of targeted ther-
apies (Weinstein, 2008). The tissue-specific variations
are classified as prognostic or predictive biomarkers. A
prognostic biomarker is defined as a measurable disease-
related parameter that is associated with clinical out-
come. On the other hand, a predictive biomarker pro-
vides information on the expected response to a specific
therapy, therefore identifying patients who are respon-
sive to a specific treatment, and/or predisposed to toxi-
city. Interestingly, BRAF mutations provide prognostic
information in colorectal cancer, but they are predictive
in melanoma (Chapman et al., 2011).
3 Genetic influences on drug
pharmacokinetics
The administration of a drug is followed by multiple
processes, which comprise the pharmacodynamic events
through which its effects manifest themselves; and phar-
macokinetic events, through which the drug becomes
subject to modification by physiological systems. Such
pharmacokinetic events may include bioactivation to the
active form, as well as various detoxification processes,
which occur prior to elimination. A group of enzymes,
the Cytochrome P450 (CYP450) family, are the ma-
jor contributors to drug activation and metabolic pro-
cesses (Guengerich, 2008; Ortiz de Montellano, 2013).
CYP450 genes are highly polymorphic, resulting in vari-
able activity of enzymes and hence variable processing
of the drug within human physiology. Of interest, the
polymorphic nature of these enzymes is even more pro-
nounced across different ethnic groups (McGraw and
Waller, 2012). The Human Cytochrome P450 Allele
Nomenclature Committee maintain a public database,
that details all known CYP450 gene alleles and the in-
fluence of these alleles on specific CYP450 enzyme activ-
ities (Human Cytochrome P450 (CYP) Allele Nomen-
clature Committee., 2013). Examples of CYP2D6 func-
tional variants are discussed further below.
3.1 Biotransformation of prodrugs
The development of prodrugs provides the chemical ap-
proach to overcome the therapeutic barriers of some
drugs, such as mal-absorption, inadequate distribution
to specific destinations in the body and premature
detoxification, which may, for example, occur during the
hepatic first pass effect. Prodrugs are administered as
pharmacologically inactive or low activity compounds
and require prior conversion to the pharmacologically
active metabolite in order to function. The exploita-
tion of endogenous enzymatic systems for the bioactiva-
tion of prodrugs may be influenced by genetic variations
within populations and ethnic groups that are associ-
ated with an increased, reduced or even no enzymatic
activity.
3.1.1 Dopa decarboxylase
One of the best known pro-drug applications has been
the development of L-Dopa for the management of
Parkinson’s Disease (PD). L-Dopa crosses the blood
brain barrier, and is metabolized to dopamine in the
brain by aromatic L-amino acid decarboxylase (com-
monly called DOPA decarboxylase, DDC). Directly ad-
ministered dopamine would be unable to cross the blood
brain barrier and would exert several peripheral adverse
effects, making it unsuitable for management of PD. The
actions of L-dopa-generated dopamine are further cen-
tralized to the brain by the co-administration of car-
bidopa, a peripheral dopamine decarboxylase inhibitor,
which effectively minimizes peripheral metabolism of L-
dopa to dopamine. Alterations in the function or ex-
pression of DDC may therefore be expected to influence
L-Dopa treated PD management outcomes. Indeed, two
DDC gene variants (rs921451 - an intronic T>C sub-
stitution, and rs3837091 - a four-base AGAG deletion
in the non-translated exon 1) that show significant de-
creases in L-dopa treated PD patient management out-
comes have recently been reported (Devos et al., 2014).
3.1.2 CYP2D6
Within the family of CYP450 enzymes, CYP2D6 is per-
haps the most pharmacogenetically-relevant member.
This is in view of its participation in the metabolic path-
ways of multiple drugs, originating from different phar-
macological classes (e.g. selective serotonin reuptake in-
hibitors, opioids, tricyclic antidepressants, B-adrenergic
antagonists, antipsychotics, antiarrhythmics), and the
highly polymorphic nature of the gene. The enzyme
is important both in lieu of its drug metabolizing and
detoxification properties (discussed separately further
down), as well as a participant in the metabolic acti-
vation of some prodrugs.
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Table 1: A non-exhaustive list of genes, for which known alleles influence the outcomes of specific
drug therapy.
Gene Drug(s) Outcome Reference
affected
ABCB1 Various Variants causing ABCB1 overexpression increase cellular
efflux and reduce activity of affected intracellular-acting
drugs. Variants causing low ABCB1 expression tend to
increase adverse effects due to low efflux and intracellular
drug accumulation.
(Franke et al., 2010)
OATP1B1 rosuvastatin OATP1B1*5 homozygotes exhibit higher plasma levels of
rosuvastatin
(Choi et al., 2008)
SLCO1B1 simvastatin Increased risk of myopathy in patients with the rs4149056
C-variant
(Brunham et al.,
2012)
SLCO1B1 simvastatin Variant rs4149056 associated with myopathy in patients
on 80mg daily simvastatin
(Carr et al., 2013)
UGT1A1 irinotecan UGT1A1*28 allele causes low drug metabolism and po-
tential life threatening effects including myelosuppres-
sion, arrhythmia, neutropenia, thrombocytopenia and di-
arrhoea
(Dias et al., 2012)
G6PD dapsone G6PD deficient individuals may be at an increased risk of
haemolytic adverse reactions
(Mason et al., 2007)
G6PD nitrofurantoin G6PD deficient individuals may be at an increased risk of
haemolytic adverse reactions
(Youngster et al.,
2010)
VKORC1 warfarin G-1639A allele causes increased bleeding risk especially
when present with CYP2C9*2 or CYP2C9*3 alleles
(Santos et al., 2013;
Yang et al., 2013)
POLG valproic acid Increased risk of potentially fatal valproate-induced acute
liver failure, especially in patients with the Q1236H sub-
stitution.
(Stewart et al., 2010)
NAT2 isoniazid,
rifampicin
NAT2 slow acetylator genotypes *5, *6 and *7 are asso-
ciated with higher risk of anti-tuberculosis drug-induced
liver injury
(Wang et al., 2012)
CYP2C9 warfarin CYP2C9*3 homozygotes exhibit an extended warfarin
half-life with possible haemorrhagic events
(Santos et al., 2013;
Yang et al., 2013)
CYP2D6 codeine CYP2D6 ultrarapid metabolizers may show opioid toxic-
ity due to extensive metabolism of codeine to morphine
(Kirchheiner et al.,
2007)
CYP2D6 amitriptyline,
nortryptiline
CYP2D6 ultrarapid metabolizers experience no response,
while poor metabolizers experience drug toxicity at con-
ventional dosages
(Teh and Bertilsson,
2012)
CYP2D6 tamoxifen CYP2D6*10 homozygotes experience poor response to ta-
moxifen
(Kiyotani et al., 2012)
DDC L-dopa DDC rs921451 and rs3837091 variants are associated
with poor L-dopa-treated Parkinson’s disease manage-
ment outcomes
(Devos et al., 2014)
TPMT azathioprine TPMT*2, TPMT*3 or TPMT*4 alleles have a low TPMT
activity, and patients show azathioprine toxicity
(Ford and Berg, 2010;
Relling et al., 2011)
UGT1A1 irinotecan Variant *28 associated with high risk of neutropenia (Perera et al., 2008)
ALOX5 ABT-761,
zileuton
Patients carrying non-pentarepeat Sp1 promoter variants,
express low ALOX5, and show reduced response to 5-LOX
inhibitors
(Drazen et al., 1999)
ADRB2 carvedilol CHF patients who are Gln27 homozygotes show lower re-
sponse to treatment than Glu27 homozygotes or heterozy-
gotes.
(Kaye et al., 2003)
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ADRB2 salbutamol
salmeterol
Variant Gly16 associated with lower response to B2-
adrenoceptor agonists
(Hall et al., 1995; Lip-
worth et al., 2013)
OPRM1 morphine and
other opioids
A118G allele associated with reduced surface receptor ex-
pression and low response to exogenous opioids
(Zhang et al., 2005;
Kroslak et al., 2007)
NR3C1 glucocorticoids Variants Ala229Thr and Ile292Val associated with de-
creased receptor ligand binding affinity; variant T746C
and haplotype 237delC/C238T/G240C associated with
lower glucocorticoid receptor expression.
(Niu et al., 2009)
NR3C1 glucocorticoids Glucocorticoid receptor promoter BclI G allele associated
with glucocorticoid resistance
(Pietras et al., 2011)
Within the latter perspective, the CYP2D6 gene was
extensively studied within the context of tamoxifen
metabolism. Tamoxifen is used to treat oestrogen recep-
tor positive breast cancer patients, and is metabolised
to endoxifen, a more potent molecule, by CYP2D6. The
wild type CYP2D6 (CYP2D6*1) generates an enzyme
with normal activity. The variants *3, *4 and *5 have
null activity and the variants *9, *10 and *17 have
a decreased enzyme activity. Compared to extensive
metabolisers (EMs) having both wild type alleles, pa-
tients with one null allele, or with one or more decreased
activity alleles have an ‘intermediate metabolism’ (IM)
phenotype, whilst patients carrying two null alleles are
‘poor metabolisers’ (PM). This variation carries ther-
apeutic implications in patient tamoxifen sensitivity
(Crews et al., 2012).
Codeine, an opiate agonist indicated for the relief of
mild to moderately severe pain, is converted to an ac-
tive metabolite, morphine, via the CYP2D6 enzyme, in
order to exert its analgesic activity. The analgesic ac-
tivity of codeine is therefore due to the combined action
of the weak parent molecule and the potent CPY2D6-
dependent metabolite, morphine; thus making codeine a
prodrug. The presence of a CYP2D6 allele, which gener-
ate a low activity enzyme (poor metabolisers, such as in-
dividuals carrying CYP2D6*4, *5, *6, or *7 alleles) has
been associated with a reduced codeine response, while
high CYP2D6 activity in ultrarapid metabolisers (due
to CYP2D6 gene copy number variation), have been re-
ported to induce morphine toxicity with conventional
codeine doses (Gasche et al., 2004).
CYP2D6 alleles, which mainly consist of haplo-
types rather than single SNPs, have been classified
by The Human Cytochrome P450 Allele Nomencla-
ture Committee, and the specific genotype of each
allele is archived at an official database hosted at
http://www.cypalleles.ki.se/cyp2d6.htm.
3.1.3 Carboxylesterases
Carboxylesterases represent a class of prodrug bioacti-
vating enzymes that are widely distributed in tissues
including plasma, liver, intestine and other biological
fluids (Hosokawa, 2008). They metabolize prodrugs,
such as olmesartan medoxomil (an angiotensin II re-
ceptor antagonist) and oseltamivir (an antiviral agent)
to their respective pharmacologically active metabolites
olmesartan (Ishizuka et al., 2010) and oseltamivir car-
boxylate (Zhu and Markowitz, 2009). The identified car-
boxylesterase 1 variant Gly143Glu, has been reported to
reduce the activity of the prodrug-activating enzyme to
25% of the wild type, and the Asp260fs variant ablates
activity completely. This may have serious implications,
with respect to the efficacy of oseltamavir in patients
carrying these variants (Zhu and Markowitz, 2009).
The inhaled glucocorticoids beclomethasone and ci-
clesonide are also activated by lung esterases. Inhaled
beclomethasone diproprionate is metabolised to the
more active beclomethasone-17-monopropionate, while
ciclesonide, an inactive prodrug, is metabolised in the
lungs to the pharmacologically active desisobutyryl-
ciclesonide. Although genetic variability in various es-
terase genes has been described (Wu et al., 2004; Cha-
rasson et al., 2004), pharmacogenetic evidence for their
relevance to bioactivation-associated pharmacology is
lacking. There is evidence, however, to indicate pharma-
cogenetic importance of these enzyme systems as detox-
ifying agents in the metabolism of active drug molecules
such as methylphenidate (Zhu et al., 2008), where spe-
cific SNPs have been shown to drastically alter the rate
of metabolism.
3.2 Membrane transporters
Drug transport across cell membranes may occur ei-
ther by passive mechanisms, or through the media-
tion of specific cell-membrane proteins which actively
transfer the drug molecule between the extracellular
environment and the intracellular milieu. More than
400 membrane transporters are known to be coded for
by the human genome, and these are differentially ex-
pressed in various tissues. Genetic variability in the
two major eukaryotic transporter families, the ATP-
binding cassette (ABC) and Solute Carriers (SLC), is
recognised to have major influences on drug therapeu-
tic efficacy and adverse reactions. Such changes may
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be brought about by functional polymorphic variation
which influences either the eukaryotic ABC-mediated ef-
flux functions, or the SLC uptake efficiency, or both. A
database of known transporters may be accessed at the
Human Membrane Transporter Database, available at
http://lab.digibench.net/transporter/ (Yan and Sade´e,
2000).
3.2.1 ATP-binding cassette (ABC) transporter
family
P-glycoprotein (Pgp)
P-glycoprotein (Pgp), a major transporter of the ABC
family, is encoded for by the ABCB1 gene (previously
known as MDR1) and mediates the ATP-dependent
efflux of drugs from cells. It is expressed in var-
ious tissues including intestinal, hepatic and renal.
It also contributes to the maintenance of the blood-
brain barrier system through endothelial expression
in the central nervous system. Pgp substrates orig-
inate from diverse pharmacological classes, and in-
clude immunosuppresants, cardiovascular agents, anti-
depressants and anti-epileptic agents, as well as cyto-
toxic drugs. ABCB1 overexpression is a major concern
in cancer chemotherapy since it induces resistance to
cytotoxic agents through increased cellular efflux. For
example, high-expression inducing ABCB1 G2677T and
G2995A SNPs have been identified in tumour patients,
in drug-resistant cell lines (e.g. colon cancer cell lines
and glioblastoma cell lines) and also in cells from re-
fractory malignant malignomas. ABCB1-knockout mice
show increased tendency toward dose-related adverse
drug reactions, increased blood brain barrier transport
and a degree of altered pharmacokinetics to a plethora of
drugs including paclitaxel, loperamide, vinblastine, iver-
mectin, digoxin and cyclosporine. This is accompanied
by drug accumulation in the brain, liver and intestine.
The ABCB1 C3435T SNP is associated with low in-
testinal Pgp expression, especially in homozygotes, and
these comprise about 25% of Caucasians. The reduced
intestinal cellular Pgp efflux activity in these individ-
uals has been associated with increased plasma levels
of administered digoxin, due to increased uptake of the
drug from the gastrointestinal tract. There are about
20 known human ABCB1 variants to date, and their
functional relevance is still coming to light. The differ-
ential expression of this gene and its recognised genetic
polymorphic profile makes it an important potential tar-
get for altered pharmacokinetic behaviour of drug sub-
strates, and the subsequent pharmacodynamic implica-
tions. For example, high Pgp activity induces cellu-
lar efflux of glucocorticoids such as prednisolone, dex-
amethasone and beclomethasone monopropionate (the
active metabolite of the pulmonary administered be-
clomethasone dipropionate), thus decreasing their clini-
cal response. There is also evidence to show that gluco-
corticoids upregulate Pgp expression and may therefore
amplify the effects of ABCB1 allele-specific high activity
variants (Crowe and Tan, 2012).
3.2.2 Solute Carrier (SLC) transporter family
Organic anion-transporting polypeptides
(OATP)
Organic Anion-Transporting Polypeptides (OATP),
the major SLC-type transporters, have received special
attention due to their involvement in the cellular
influx of several drugs, particularly statins (HMG-CoA
reductase inhibitors). OATPs are highly expressed in
hepatic tissue, where they are involved in the clearance
of drugs from portal circulation in preparation for
subsequent biliary excretion. The influx transporter
OATP1B1 (coded for by the SLCO1B1 gene) has, in
particular, been well studied due to its major role in
the hepatic uptake of many drugs. For example, the
SLCO1B1 alleles *2 (T217C), *3 (T245C, A467G), *5
(T521C), *9 (G1463C), *12 (T217C, A1964G), *13
(T245C, A467G, A2000G), *15 (A388G, T521C), and
*18 (A388G, G1463C) have all been associated with
decreased rosuvastatin transport activity. SLCO1B1*15
homozygotes in particular have been reported to exhibit
significantly higher AUC values for concentration-time
curves of plasma rosuvastatin, possibly due to decreased
intracellular drug influx (Choi et al., 2008).
Na+-taurocholate cotransporting polypep-
tide (NTCP)
A variant of another SLC member, the Na+-
taurocholate cotransporting polypeptide *2 allele
(NTCP *2, C800T), is known to have a near complete
loss of function for bile acids; however it exhibits a
profound gain of function for rosuvastatin, resulting
in a clinically relevant reduction in plasma levels
compared to the wild-type allele. The outcome may
be further complicated by the contribution of OATPs
such as OATP1B3, OATP2B1 and OATP1A2, which
are also known to mediate statin transport and exhibit
functional polymorphic variation in humans (Choi
et al., 2011).
Organic anion transporter family member
1B1 (SLCO1B1)
The solute carrier organic anion transporter family
member 1B1 (coded for by SLCO1B1) is expressed
and localised in the cell membrane of hepatocytes and
is involved in uptake of xenobiotic and endogenous
substances (Karlgren et al., 2012). During the recent
years, the SLCO1B1 SNP T37041C (rs4149056) began
to receive special attention following the development
of myopathy in patients on high dose simvastatin (80mg
daily) participating in the 2008 SEARCH case-control
study, and who were later recognised to carry the minor
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C allele. The localisation of the transporter in the hep-
atic plasma membrane is disturbed in the presence of
this variation, resulting in a higher simvastatin plasma
concentration and increased skeletal muscle drug expo-
sure (Pasanen et al., 2006). The FDA strongly advises
against 80mg daily simvastatin doses for patients who
are heterozygous or homozygous for the C allele. The
FDA also advises caution for long term use of 80mg
daily doses in wild type 37041T homozygotes. These
recommendations have also been incorporated into the
SLCO1B1 Clinical Pharmacogenetics Implementation
Consortium (CPIC) guidelines (Wilke et al., 2012).
3.3 Drug metabolism
Drug metabolism is a complex process, often involv-
ing multiple parallel pathways, during which drugs are
converted to breakdown products (usually of lower tox-
icity) in preparation for elimination from the physiolog-
ical system. The rate of drug breakdown is important
in reducing toxicity level and maintaining a pharmaco-
logical dose within the therapeutic window of the active
ingredients.
3.4 Thiopurinemethyltransferase
(TPMT)
Thiopurinemethyltransferase (TPMT) is a phase II bio-
transformation cytosolic enzyme catalysing the methy-
lation of thiopurines into inactive metabolites. The
TPMT enzyme is highly expressed in the liver, while
its expression is low in the brain and lung (Ford and
Berg, 2010). Interestingly, the TPMT activity in ery-
throcytes correlates with the hepatic enzyme activity,
meaning that phenotypic assessment can be performed
in erythrocyte lysates (Wu, 2011). The TPMT gene is
polymorphic and despite ethnic variability, the minor
alleles TPMT*2, TPMT*3A and TPMT*3C account
for the majority of the low-activity variants (Relling
et al., 2011). TPMT activity shows a trimodal distri-
bution with heterozygotes having intermediate activity
(IM), homozygotes or compound heterozygosity show-
ing low or absent activity (PM), and the normal geno-
type TPMT*1/*1 representing the normal activity of
the enzyme (EM). The major drug for which TPMT ac-
tivity is relevant is mercaptopurine, the active metabo-
lite of the prodrug azathioprine. Mercaptopurine is
detoxificated by several metabolic pathways, including
a major one that involves the enzyme TPMT. Azathio-
prine patients with low TPMT activity are at a strong
risk of developing severe, potentially life-threatening,
bone marrow toxicity when treated with conventional
doses of azathioprine or mercaptopurine (Anon, 2009;
Ford and Berg, 2010).
3.5 UDP Glucuronosyltransferase 1
(UGT1A1)
Irinotecan, a topoisomerase I inhibitor used to treat sev-
eral solid tumour types, as well as its active metabolite
SN-38, exert their effects by preventing re-ligation of
single-stranded DNA breaks induced during the DNA
synthesis phase of cellular replication. SN-38 subse-
quently undergoes glucuronidation primarily in the liver
by UGT1A, followed by excretion through the kidneys.
Adverse effects of irinotecan treatment include severe
diarrhoea, myelosuppression, and neutropenia. These
effects are induced by inefficient UGT1A1-dependent
metabolism of SN 38 (Mathijssen et al., 2001). UGT1A1
gene variants, which demonstrate a reduced enzyme ac-
tivity or expression, cause an accumulation of the ac-
tive metabolite SN-38 at conventional urinotecan dos-
ing. Of primary importance is the high frequency vari-
ant UGT1A1*28, which results in at least 70% reduction
in expression levels (Perera et al., 2008). Cancer pa-
tients homozygous for the *28 allele, receiving irinotecan
at 350 mg/m
2
every 3 weeks, have a high risk of suffering
from neutropenia. Genotype-guided phase I studies de-
termined the maximum tolerated dose in *1/*1, *1/*28,
and *28/*28 patients to be 390, 340, and 150 mg/m
2
,
respectively (Marcuello et al., 2011). Indeed, the FDA
recommends an initial dose reduction of irinotecan for
patients who are homozygous for UGT1A1*28, this is
supported by the CPIC and Dutch Pharmacogenetics
Working Group (DPWG) guidelines, which recommend
a 30% dose reduction in irinotecan administration for
this genotype (Relling and Klein, 2011).
3.6 Uridine diphosphate glucuronosyl-
transferase 2B7 (UGT2B7)
The UGT2B7 gene is highly expressed in the liver,
and is pharmacogenetically relevant due to its impor-
tance in the detoxification of morphine. The gene prod-
uct converts the drug to the inactive form morphine-3-
glucuronide and the low efficacy morphine-6-glucuronide
metabolites. Two tightly linked UGT2B7A polymor-
phisms, the 161C/T promoter SNP and the 802C/T
SNP, are associated with low glucuronidation of mor-
phine, with consequent clinical implications in opioid
efficacy (Sawyer et al., 2003; Eissing et al., 2012).
3.7 Cytochrome P450 enzyme system
(CYP450)
Some examples involving CYP450 members concerned
in prodrug activation have already been cited earlier in
this article. However, the metabolic detoxification role
of these enzymes has more widespread implications,
and has been much more thoroughly studied. Indeed,
this enzyme system has been reported to partake in
over 75% of drug detoxification processes that occur in
man.
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CYP2D6
The CYP450 member, which is most relevant to
drug metabolism processes is the D6 enzyme of the
CYP450 family 2 (CYP2D6). This enzyme is capable
of metabolizing drug substrates that originate from
chemically and pharmacologically distinct groups, in-
cluding antidepressants, antipsychotics, antiarrhythmic,
anti-emetics, beta-blockers and opioids. It is estimated
that about 25% of currently marketed drugs have
their metabolism in some way influenced by CYP2D6
activity, with about 100 commonly used drugs being
major substrates for the enzyme.
The CYP2D6 gene is highly polymorphic. The
Human Cytochrome P450 (CYP) Allele Nomen-
clature Committee currently lists over 100 known
CYP2D6 genotypes, which may result in the expres-
sion of a normal or altered-activity CYP2D6 enzyme
(http://www.cypalleles.ki.se/cyp2d6.htm). According
to the specific allele combination carried, individuals
may be classified as poor, intermediate or extensive
metabolisers. Moreover, copy number variations of
the CYP2D6 gene have also been described in the
literature (Sheng et al., 2007), leading to the ultrarapid
metaboliser phenotype. It has been estimated that as
much as twenty million inhabitants of Western Europe
are ultrarapid metabolisers, with at least a copy number
of 2 functional CYP2D6 alleles (Ingelman-Sundberg,
2005). Extensive and ultrarapid metabolisers may
show insufficient or no clinical response to CYP2D6
enzyme substrate drugs used at standard conven-
tional dosages, while poor metabolisers run the risk
of drug accumulation carrying consequent adverse
reactions. For example, adverse effects to metoprolol,
nortryptiline, perphenazine, thioridazine, haloperidol
and perhexiline have been reported to be much more
common in poor CYP2D6 enzyme metabolisers, while
extensive metabolisers tend to show reduced effects
(Teh and Bertilsson, 2012). Post-menopausal oestrogen
receptor positive breast cancer patients on tamoxifen,
who are also CYP2D6*4 homozygotes, show a sig-
nificantly reduced relapse-free survival period when
compared to wild type patients. Studies in Asian and
Dutch populations have reported similar low tamoxifen
response in breast cancer patients who are CYP2D6*10
homozygotes. It has been suggested that an increase of
50 to 100% of the normal tamoxifen dose is required for
patients who are heterozygous or homozygous for the
CYP2D6*10 allele, in order to maintain normal blood
levels (Kiyotani et al., 2012).
The importance of CYP2D6 pharmacogenetics is fur-
ther accentuated by the fact that the allelic frequencies
of this gene are well known to exhibit diverse ethnic
discrepancies, and alleles which may be present in one
population or ethnic group, may be completely absent
in another. This adds complexity to the genotype-
phenotype interpretations.
CYP2C9
CYP2C9 gene polymorphic variability has been re-
ported to be of pharmacogenetic relevance in the
metabolism of warfarin (a commonly used antico-
agulant) and celecoxib (a cyclooxygenase 2-specific
non-steroidal anti-inflammatory drug). The nonsyn-
onymous polymorphisms CYP2C9*2 (rs1799853) and
CYP2C9*3 (rs1057910) express a reduced activity
variant of the enzyme. CYP2C9*3 homozygotes may
exhibit a warfarin half-life of 90-200 hours, thus poten-
tially leading to serious warfarin-induced haemorrhagic
events (Jorgensen et al., 2012). The same CYP2C9*3
genotype also increases the half-life of celecoxib by
about 2.7 fold, and *3 homozygotes therefore warrant
lower doses of the drug in order to avoid dose-related
adverse effects (Prieto-Pe´rez et al., 2013).
4 Genetic influences on drug
pharmacodynamics
4.1 Cell signalling
About seventy percent of drugs licensed for human
therapeutic use mediate their action through their in-
teraction with one or more cellular receptor proteins.
Two thirds of these are dependent on one or more mem-
bers of the G-protein coupled receptor superfamily. The
rest act via nuclear or kinase receptors. Drug receptors,
therefore, often constitute the first interface between a
therapeutically administered drug and cellular physiol-
ogy. Genetic variability in the receptors themselves, or
any proteins involved in receptor signalling pathways,
may exert a potential influence on therapeutic outcomes.
4.1.1 G-protein coupled receptors (GPCRs)
Genome sequencing data suggests that the human
genome codes for about 800 different GPCRs. Nearly
400 of these are currently indexed in the International
Union of Basic and Clinical Pharmacology online
database (IUPHAR database, 2013), together with
additional data such as: known ligands, gene and
protein records and signalling pathways. The intricate
signalling and trafficking pathways of GPCRs provide
several targets within which genetic variability may
influence drug efficacy, potency and safety. Besides
the commonly reported ligand binding and subsequent
signalling pathways, GPCRs may also show constitu-
tive activity and may undergo other processes such
as: desensitization, supersensitization, downregulation,
upregulation, homodimerization, heterodimerization,
trafficking and recycling (Bosier and Hermans, 2007;
http://dx.medra.org/10.7423/XJENZA.2014.1.03 www.xjenza.org
Pharmacogenetics: the science of predictive clinical pharmacology 22
Thompson et al., 2008b; Thompson et al., 2008a).
The most common loci that are known to cause
perturbation of GPCR function however, remain to be
those within the actual receptor proteins and G-protein
complexes, as well as their respective gene promoters.
We present some examples of pharmacogenetically
relevant GPCR variants.
B2-adrenoceptor
One of the most pharmacogenetically studied GPCRs
is the B2-adrenoceptor, coded for by the ADRB2 gene
located at 5q31-q32. Polymorphic variations in this
gene have been associated with: (i) perturbations of
molecular pharmacological actions, such as alterations
in downregulation activity, (ii) changes in therapeutic
outcomes of B2-adrenoceptor agonist treatment and
(iii) changes in clinical manifestations of different
diseases. For example, the widely studied Arg16Gly
receptor variant displays enhanced agonist-promoted
downregulation, while the Gln27Glu polymorphism ap-
pears to confer resistance to downregulation. Patients
with asthma carrying the Arg16Gly B2-adrenoceptor
variant, have been reported by some research groups to
exhibit a lower lung function than Arg16 patients, and
also show an increased incidence of familial nocturnal
asthma. These patients have also been reported to be
less responsive to the commonly used B2-adrenoceptor
agonist bronchodilator treatment, probably due to
reduced cell surface density of B2-adrenoceptors. How-
ever, other clinical studies in asthmatic patients have
reported ADRB2 genotype-phenotype associations in
small-scale adult clinical studies, that conflict with
earlier findings (Bleecker et al., 2007), and research
workers have argued that sample size, patient selection,
and concomitant treatment could confound the study
outcomes. (Hall et al., 1995; Tan et al., 1997; D’Amato
et al., 1998; Lee et al., 2004; Tattersfield and Hall,
2004). Recently, (Lipworth et al., 2013) studied 62
persistent asthmatic children who were homozygous
for the ADRB2 Arg16 polymorphism and were being
treated with regular inhaled fluticasone. In these Arg16
homozygotes, add-on therapy, with the leukotriene
receptor antagonist montelukast, produced significantly
greater clinical improvements than the long acting B2
adrenoceptor agonist salmeterol when assessed after
one year. The authors suggest that these preliminary
data indicate that genotyping of the ADRB2 codon
16 may be a useful pharmacogenetic marker, which
could have potential to be used to optimize asthma
management (Lipworth et al., 2013; Sayers, 2013).
Leukotriene receptors
Leukotrienes constitute an important group of pro-
inflammatory and bronchoconstrictory molecules,
derived via the 5-lipoxygenase-mediated (5-LOX)
arachidonic acid metabolism pathway. The major
cysteinyl leukotrienes comprise LTC4, LTD4 and LTE4,
while LTB4 which lacks cysteine, is classified separately.
The former exert their actions via agonism at the the
cysteinyl leukotriene receptor CysLTR1 (and to a lesser
degree via CysLTR2), while the latter exerts its actions
via LTB4R and LTB4R2. Antagonism of the CysLTR1
receptor by drugs such as zafirkulast, montelukast and
pranlukast is an important therapeutic modality in the
management of asthma and allergic rhinitis. Although
genetic CysLTR1 variability is well documented,
functional pharmacological effects have mainly been
observed when CYSLTR1 SNPs are present together
with SNPs in the 5-lipoxygenase gene ALOX5. For
example, ALOX5 promoter variants, involving poly-
morphisms which result in an alteration of the number
of Sp1 binding motifs, from the wild-type penta-Sp1
repeat, are known to result in low 5-lipoxygenase ex-
pression. This results in a reduced contribution of the
specific 5-LOX pathway to overall airway inflammatory
pathology, consequently reducing the clinical efficacy
of both 5-LOX enzyme inhibitors as well as CysLTR1
receptor inhibitors (Kalayci et al., 2006). The CysLTR1
G300S variant confers a stronger potency to the potent
bronchoconstrictor LTD4, and may confer low response
to CysLTR1 receptor antagonists at conventional doses
(Thompson et al., 2007; Duroudier et al., 2009)
Opioid receptors
Opioids exert their actions through their agonistic
properties on three major classical GPCRs, namely
the μ-receptor coded by the OPRM1 gene at 6q24-q25,
the κ-receptor coded by OPRK1 at 8q11.2 and the
δ-receptor coded by OPRD1 and located at 1p36.1-
p34.3. These receptors are differentially expressed,
exist as different subtypes, and mediate the various
opioid effects such as analgesia, euphoria, dysphoria
and dependence. A fourth receptor, orphanin FQ,
encoded by the OPRL1 gene located at 20q13.33, is
also known to be activated by opioid ligands.
The A118G, (rs1799971, allelic frequency=0.19) SNP
in the OPRM1 gene has probably been the most stud-
ied. Molecular work suggests that the G allele results in
a gain of function of the μ-receptor to the endogenous
opioid B-endorphin, but a loss of function to exogenously
administered opioids such as morphine. This has been
corroborated with clinical evidence, where the G allele
has been associated with a reduced morphine response
in cancer and post-operative patients. However, in a
meta-analysis of opioid pain studies, the authors could
only detect weak associations with increased morphine
dose requirements in homozygous carriers of the variant
G allele. This suggests that clinical opioid response
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may be the result of complex interactions between
various pharmacogenetic variants. It could also be due
to other common functional variants which have not
been studied during meta-analysis and could therefore
confound the outcome. (Mura et al., 2013; Crist and
Berrettini, 2013). For example, in vitro studies suggest
that another common variant, the exonic OPRM1
C17T, may be a relevant marker of low buprenorphine
efficacy in opioid dependence management therapy
(Bajada, 2010). Moreover, opioid response is known
to also be influenced by other genetic polymorphisms,
besides those affecting the receptors themselves. Such
genes include those that code for metabolic enzymes
such as CYP2D6, CYP3A4, CYP3A5, UGT2B7 and
membrane transporters such as ABCB1.
4.1.2 Nuclear receptors
The nuclear receptor family, although much smaller
than the GPCR group, comprises important targets for
pharmacological management.
Glucocorticoid receptor
The human glucocorticoid receptor (hGR), a 94-kDa
protein encoded by the NR3C1 gene located at 5q31-
q32, has received significant pharmacogenetic attention,
mainly due to the wide array of glucocorticoid agonists
available in the therapeutic repertoire. Glucocorticoid
responses are the fruit of complex multiple pathways,
involving the activation or repression of multiple genes,
and genotype-phenotype associations, are therefore
often very difficult to establish. Moreover, although the
human genome only contains one known glucocorticoid
receptor gene, there are several receptor isoforms which
are the result of polymorphisms, alternative splicing
and alternative translational initiation. Furthermore,
hGR isoforms may also be subject to a variety of
posttranslational modifications, resulting in altered
receptor function.
Within a sample of 240 individuals, Niu and co-
workers identified 108 polymorphisms present in a
range of exonic, intronic and untranslated regions of
the NR3C1 gene. Subsequent functional analysis of
a candidate subset of these variations identified some
of these regions to be associated with higher hGRα
protein expression (Phe(65)Val and Asp(687)Glu),
some associated with decreased ligand binding affin-
ity (Ala(229)Thr and Ile(292)Val) and others to be
associated with decreased hGRα transcript expres-
sion (746T>C and haplotype 237delC / 238C>T
/ 240G>C). These functional polymorphisms were
present in allelic frequencies in the range of 5.8% and
18.3% in different ethnic groups, and could contribute
to reduced glucocorticoid sensitivity in a clinical setting
(Niu et al., 2009).
The major issues associated with glucocorticoid
therapy relate to the potential adverse effects (e.g.
hypothalamic-pituitary-adrenal axis suppression, devel-
opment of cushingoid features, hyperglycaemia, easy
bruising, immunodeficiency) and to a patient subset
who wish to refrain from this treatment. Both variables
may not necessarily be directly associated to allelic
variation within the NR3C1 gene, but may also be the
result of downstream effectors which are responsive
to hGR-induced pathways, or metabolic pathways
which modify the pharmacokinetics of these drugs.
For example, allelic variations in 8 genes (CNTNAP2,
LEPR, CRHR1, NTAN1, SLC12A3, ALPL, BGLAP,
APOB) have been associated with prednisolone-induced
hypertension following a 28-day treatment remission
induction of acute lymphoblastic leukaemia in children
(Kamdem et al., 2008). Most of these genes are
involved in the hypothalamic-pituitary axis pathway.
Furthermore, as discussed earlier, gain of function
polymorphisms in the ABCB1 gene, coding for the Pgp
efflux transporter, have also been reported to reduce
glucocorticoid efficacy by actively lowering intracellular
glucocorticoid concentrations.
The main cellular hGR signalling activity is at-
tributed to the ubiquitly expressed wild type isoform,
hGRα. The B-isoform, a shortened splice variant of
NR3C1, is also ubiquitly expressed, though at a lower
level than hGRα. High expression levels of hGRB are
strongly associated with glucocorticoid resistance. The
mechanism of this has been subject to many debates,
especially since in contrast to hGRα, the B-isoform
interacts poorly with heat shock proteins, does not
bind ligands, and is transcriptionally inactive. The
postulated mechanisms have included competition
for hGRα binding sites (glucocorticoid responsive
elements) on gene promoters, direct inactivation of
the hGRα isoform by heterodimerization, and the
inhibition of co-activating proteins which are necessary
for hGRα activity. More recent evidence suggests that
hGRB competes with hGRα for binding to glucocorti-
coid receptor-interacting protein 1 (also called nuclear
receptor coactivator 2 and coded for by the NCOA2
gene), thus generating an ineffective co-activator com-
plex. Furthermore, a recent paper (Vazquz-Tello et al.,
2013) has reported evidence showing that the cytokines
IL-17 and IL-23, released by infiltrating T-cells in
asthma, may contribute to hGRB upregulation and
consequently but only to a degree also contribute to
glucocorticoid insensitivity.
The differential expression of the various hGR
isoforms is driven by the selective use of at least 5
recognised hGR promoters (Russcher et al., 2007). The
activity of these transcripts is further dependent on
cell types and on promoter polymorphic variation. For
example, the G allele of the BclI hGR promoter poly-
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morphism is significantly associated with GC resistance
and with the development of severe asthma (Pietras
et al., 2011). The -22C>A polymorphism, located
upstream of the hGR gene, causes a significantly lower
transcriptional activity compared to the wild type C
allele, as determined by promoter luciferase reporter
assays in HepG2 and HEK293 cells, and is likely to be
related to lower hGRα expression in the clinical setting.
The elucidation of clear hGR-associated pharma-
cogenetic genotype-phenotype relations remains a
challenge. The complex molecular network involved
in the outcomes of glucocorticoid receptor activation,
suggests that the search for glucocorticoid pharma-
cogenetic variants should be spread over a large gene
subset. Moreover, the effects of polymorphisms on the
interrelated functions of these gene networks might be
more important than the genetic variability present in
the glucocorticoid-interacting receptor alone.
4.1.3 Enzyme pathways
The arachidonic acid cascade
Arachidonic acid is a polyunsaturated fatty acid present
in the phospholipids of cell membranes. It is released
from phospholipid molecules through the actions of
phospholipase A2 (PLA2) and is subsequently metab-
olized by a variety of pathways to products which are
normally necessary for cell function and development,
but this may cause pathologic manifestations if over-
produced. The cycloxygenase (COX) pathway, mainly
driven by the enzymes COX1 (coded for by PTGS1) and
COX2 (coded for by PTGS2), in particular, is a target
for a wide array of non-steroidal anti-inflammatory
drugs (NSAIDs), which act to inhibit their activity.
The PTGS1 gene contains two strongly linked SNPs
(A842G and C50T) which when present in heterozy-
gous patients, have been shown to significantly increase
the susceptibility of COX1 for inhibition by aspirin.
This carries the risk of increased aspirin toxicity at
conventional doses, since many NSAID adverse effects
are related to over suppression of COX activity. For
example, NSAID-induced peptic ulceration is associated
with over suppression of COX-mediated prostaglandin
E2 (PGE2) production, and high anti-platelet effect is
associated with excessive inhibition of COX-mediated
thromboxane A2 (TXA2). On the other hand, several
COX polymorphisms (PTGS1: C22T, C50T, A842G,
G128A, C644A, C714A, C10427A, G1446A; PTGS2:
G765C) have been reported to cause resistance to the
pharmacological effects of aspirin (Xu et al., 2012).
The arachidonic acid pathway is not the sole source
of NSAID-related pharmacogenetic variability. For
example, lumiracoxib, (a COX2-selective NSAID)
hepatotoxicity has been strongly associated with the
human leukocyte antigen haplotype HLA-DRB1*1501-
HLA-DQB1*0602-HLA-DRB5*0101-HLA-DQA1*0102
(Singer et al., 2010).
The lipoxygenase pathway
The enzyme 5-lipoxygenase (5-LOX) metabolizes
arachidonic acid to a family of leukotrienes, amongst
which the most important are LTB4, LTC4 and LTD4.
All of these exhibit bronchoconstrictory and mucose-
cretory properties within the respiratory tract, and
have been shown to be important mediators of airway
inflammatory diseases, such as asthma and allergic
rhinitis. 5-lipoxygenase is coded for by the ALOX5
gene located at 10q11.2, and the enzyme is activated by
the 5-lipoxygenase activating protein (ALOX5AP gene
located at 13q12). Transcriptional regulation of ALOX5
is heavily dependent on a pentarepeat SP-1 binding
motif repeat located in its promoter. Lower or higher
numbers of ALOX5 promoter SP-1 repeats have been
shown to significantly reduce ALOX5 gene expression.
Indeed, asthma patients carrying a variant SP-1 repeat
number show minimal or no improvement following
treatment with zileuton, a 5-LOX inhibitor, due to the
reduced expression of the drug target. The functional
outcome of this polymorphism can be compounded
further by concomitant polymorphic variation in other
pathway-related genes, such as 5-lipoxygenase acti-
vating protein (coded for by ALOX5AP), leukotriene
A4 hydrolase (coded for by LTA4H), leukotriene C4
synthase (coded for by LTC4S), and the leukotriene
receptors CYSLTR1 and CYSLTR2. (In et al., 1999;
Drazen et al., 1999; Telleria et al., 2008; Geiger
et al., 2009; Duroudier et al., 2009; Tantisira and
Drazen, 2009). Interestingly, the ALOX5 haplotype
[-1708G]-[21C]-[270G]-[1728A] appears to contribute
to aspirin sensitivity in asthma, and may potentially
help to identify aspirin-sensitive from aspirin-tolerant
asthmatic patients (Choi et al., 2004).
Due to the common arachidonate substrate of the
COX and 5-LOX enzymatic pathways, events occurring
within one pathway can also influence the other.
For example, COX-inhibition by NSAIDS enables
the unmetabolized arachidonic acid to shunt to the
5-LOX pathway, thus generating higher amounts of
bronchoconstrictor leukotriene products. This has
been the basis of the bronconstrictory adverse effect of
NSAIDs often seen in aspirin-intolerant asthmatics; an
effect which is exacerbated by the presence of genetic
variants which influence the 5-LOX arm of arachidonate
metabolism. The first reported such polymorphism
was the leukotriene C4 syntase (LTC4S) promoter SNP
(-444 A/C), which was associated with aspirin-induced
asthma exacerbation, potentially due to LTC4S-
mediated increased leukotriene production in carriers
of this allele (Sanak et al., 1997). This association,
which was derived from a small adult patient-based
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study, has unfortunately not been replicated by other
studies. In addition, luciferase-based promoter reporter
experiments in HeLa cells and KU812F cells have not
been able to identify any influence of these polymor-
phisms on promoter transcriptional activity. However,
this SNP does seem to contribute to lower pulmonary
function FEV1 readings in children (Sayers et al., 2003).
Tyrosine kinases
Tyrosine kinases constitute a family of enzymes that
owe their importance to their tight involvement in
proliferative cell signalling and cancer management.
Kinase variants provide a robust way to enable the
classification of patients suffering from several types
of cancers, into specific therapeutic groups, based on
pharmacogenetically-based predictive therapy outcome.
Genotyping of tyrosine kinase variants has applications
in predicting therapy efficacy as well as drug resistance.
This may be exemplified by the characterisation of the
BRC/ABL translocation in Chronic Myeloid Leukaemia
(CML). The development of imatinib, a small molecule
tyrosine kinase inhibitor, binding specifically to the
ATP pocket of the BCR/ABL kinase domain, is
intended for use in BCR/ABL positive leukaemia.
The characterization of the molecular mecha-
nism of disease thus allows for the development of
patient-targeted therapy. Targeted therapy has been
implemented in the clinic and includes the use of the
monoclonal antibodies rituximab and trastuzumab to
target CD20 positive lymphomas and HER2 positive
breast cancer cases respectively. Small molecule in-
hibitors, such as imatinib, were designed to specifically
inhibit the tyrosine kinase fusion protein bcr/abl
in CML. In addition, imatinib inhibits the receptor
tyrosine kinase, cKIT and hence targets activation of
cKIT mutants in Gastrointestinal Stromal Tumours
(GIST). Table 2 lists current therapies used to target
specific genetic aberrations.
Table 2: Examples of genetic variants that are used to enable optimum selection of specific oncology
therapy. These biomarkers, which may be identified by appropriate genotyping, can predict whether the drug
will show an adequate response or whether the patient will be resistant to its actions. The FDA advocates in
favour of predictive genotyping for the intended use of these drugs for targeted therapy.
Drug Drug Target Disease Resistance to Reference
Therapy
imatinib BCR-ABL Chronic Myeloid
Leukaemia
BCR-ABL mutations (Gorre et al., 2001;
Zhang et al., 2009)
imatinib cKit receptor Gastrointestinal Stro-
mal Tumours
KIT V654A (Rubin et al., 2010;
Chen et al., 2004)
trastuzumab
pertuzumab
HER2 receptor Breast Cancer PIK3CA mutants (Kataoka et al., 2010)
vemurafenib BRAF V600E Metastatic
Melanoma
RAS mutations (acti-
vation of MAPK)
(Chapman et al.,
2011)
erlotinib EGFR L858R; Δexon
19
Non-Small-Cell Lung
Carcinoma
EGFR (T790M) (Miller et al., 2012;
Kwak et al., 2010)
cetuximab EGFR Colorectal Cancer KRAS mutations (Lie´vre et al., 2006;
Allegra et al., 2009)
Activating tyrosine kinase mutations are central to
specific targeted therapy. Investigation of kinase deregu-
lation within particular patient groups, has led to identi-
fication of mutant tyrosine kinases associated with dis-
ease progression and therapy modulation. Of interest
is the identification of mutations in the receptor tyro-
sine kinase cKit, associated with high relapse risk in
core binding factor leukaemias (Paschka et al., 2006).
Mutations in exon 8 and 17 of the KIT gene signif-
icantly decrease the overall survival of acute myeloid
leukaemia patients with the translocations inv(16) and
t(8;21). The potential specific targeting of cKit using
small molecule tyrosine kinase inhibitors necessitates the
promotion of screening patients with core-binding factor
AML for KIT mutations. This genetic profile of specific
groups of patients gives prognostic and predictive infor-
mation of clinical relevance (Cammenga et al., 2005).
In addition to high relapse rate, therapy outcome
markers include mutations that predict resistance to
therapy. In colorectal cancer (CRC) treatment, K-Ras
mutations significantly predict resistance to anti-EGFR
therapy. Several clinical studies have shown that the
presence of a K-Ras mutation is a significant predictor
of resistance to anti-EGFR therapy in colorectal can-
cer patients (Lie´vre et al., 2006). The identification of
K-Ras mutants in CRC became part of the clinical prac-
tice protocols and clinical trials. Table 2 presents a list
of mutations that are increasingly being used to pre-
http://dx.medra.org/10.7423/XJENZA.2014.1.03 www.xjenza.org
Pharmacogenetics: the science of predictive clinical pharmacology 26
dict therapy outcome. There are various mechanisms
of resistance that account for primary and secondary
(acquired) lack of therapy response. Point mutations
in the kinase domain of the target molecule conferring
steric hindrance account for the majority of primary re-
sistance.
5 Analytical platforms for
pharmacogenetics
For several years, genotyping technology has only been
accessible through the expertise and hardware platforms
of specialized laboratories. There is now a gradual
movement to bring pharmacogenetic genotyping tech-
nology to the bedside, through portable automated
equipment, which transfers most of the onus of obtaining
good analytical quality data to the instrument, rather
than the operator. An example of this is the patented
FDA-approved Spartan RX CYP2C19 test, which anal-
yses *2, *3, and *17 alleles, and is specifically relevant
to CYP2C19-metabolized substrates, such as the anti-
platelet drug, clopidogrel. The portable genotyping de-
vice uses a buccal swab as the analyte and delivers geno-
typing results within 60 minutes, with minimal operator
intervention.
Larger scale genotyping assays remain within the do-
main of specialized centres. For example, the Affymetrix
DMET+ microarray chip is capable of simultaneously
analysing a panel of 1936 pharmacogenetically-relevant
mutations from 225 different genes consisting of 50
CYP450 genes, 45 Phase II enzymes, 64 drug trans-
porters and 66 transcriptional regulators and enzymes.
The Affymetrix Amplichip, marketed by Roche, uses
similar microarray technology applied on a smaller scale,
to provide genotype data of a panel of CYP2D6 and
CYP2C19 polymorphisms which are relevant to the
metaboliser status for specific B-adrenergic receptor in-
hibitors, antidepressants, anti-psychotics, proton-pump
inhibitors, anti-epileptics and opioids.
It is the challenge of scientists and technology to place
more pharmacogenotyping tools in the hands of drug
prescribers, to further enhance reaping the benefits of
personalized medicine.
6 Conclusion
Over one hundred drugs currently approved by the FDA,
require the inclusion of pharmacogenomic information
on the drug label (FDA, 2013). This translates to ap-
proximately 25% of patients who make use of hospi-
tal outpatients services, being prescribed one or more
drugs that have pharmacogenomic information on the
labelling (Frueh et al., 2008). For these therapeutic
groups, clinically relevant information obtained using
pharmacogenetic biomarkers is a warranted approach
to allow proper classification of patients into predic-
tive therapeutic categories. Integrating this information
into patient management protocols allows selection of
personalized targeted treatment regimes, reduces inter-
patient drug response heterogeneity, saves unnecessary
drug toxicity and decreases morbidity.
In order to accomplish this target, multiple ap-
proaches need to be conducted in parallel. Pharma-
cogenetic data must be validated through repeatability
studies and cumulated into curated repositories. In-
deed, such repositories have rapidly developed in the
last 10 years (Patrinos and Brookes, 2005; Lagoumintzis
et al., 2010). Besides the “Table of Pharmacogenomic
Biomarkers in Drug Labeling” provided by the FDA
(FDA, 2013), other noteworthy repositories are the
PharmGKB Pharmacogenomics Knowledgebase, man-
aged by the PharmGKB team at Stanford University,
California, USA (Whirl-Carrilo et al., 2012) (Pharma-
cogenomics Knowledgebase (PharmGKB), 2013) and
FINDbase, maintained by the GoldenHelix Institute of
Biomedical Research, London, UK (Georgitsi et al.,
2011) (FINDbase Genome Variation Allele Frequen-
cies Worldwide, 2013).
Actions toward translational pharmacogenetics are
needed (Squassina et al., 2010). Indeed, large scale
initiatives to consolidate pharmacogenomic data and
translation of these from bench to bedside are cur-
rently underway. The Pharmacogenomics for Every-
one (PGENI) initiative aims to focus pharmacoge-
netic data into a country-specific knowledgebase in
order to augment the relevance and applicability for
individual patients (Pharmacogenomics for Everyone
Initiative (PGENI), 2013). The Clinical Pharmaco-
genetics Implementation Consortium (CPIC), estab-
lished in 2009, is a shared project between PharmGKB
and the Pharmacogenomics Research Network. CPIC
publishes peer-reviewed guidelines to pharmacogenetic-
guided drug dosing, and simultaneously posts these rec-
ommendations to the online curated PharmGKB repos-
itory (Clinical Pharmacogenetics Implementation Con-
sortium (CPIC), 2013).
Pharmacogenetic stratification of patients in clinical
trials opens a new door to enable early identification
of specific drug responses in a genetically defined pa-
tient subgroup. The inclusion of such stratification,
from drug development Phase II clinical trials onwards,
generates drug outcome data that may be otherwise ge-
netically confounded and therefore not statistically iden-
tifiable. This is especially relevant for diseases such as
asthma, for which therapies directed at new drug targets
are currently under development (Portelli and Sayers,
2012). This approach has to be combined with the use
of new large scale high throughput omics-based tech-
nologies, in order to identify novel functional genetic
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loci, which either on their own or in combination, can
be used as predictive biomarker panels.
Pharmaceutical and diagnostic companies are work-
ing together to formulate robust pharmacogenetic tests
which could be used to predict the best drug at the right
dose for a specific patient. This goal aims to achieve
safer and more effective patient outcomes and in the long
term, decrease pharmacoeconomic-related costs. Var-
ious issues including complex genotype-phenotype as-
sociations, variable penetrance, gene-gene interactions,
and ethnic-dependent differences in allelic distributions,
make this a very challenging task. Its success depends
entirely on the concerted efforts of industry, academia
and regulatory agencies, combined with the provision
of relevant educational services for drug prescribers and
associated healthcare providers.
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